MaxCyte, Inc. (MXCT) Bundle
Understanding MaxCyte, Inc. (MXCT) Revenue Streams
Revenue Analysis
MaxCyte, Inc. (MXCT) revenue streams primarily consist of product sales and services in the biotechnology sector.
| Revenue Source | 2022 Revenue ($) | 2023 Revenue ($) | Year-over-Year Growth |
|---|---|---|---|
| Product Sales | 33,471,000 | 41,286,000 | 23.3% |
| Service Revenue | 12,589,000 | 15,742,000 | 25.0% |
| Total Revenue | 46,060,000 | 57,028,000 | 23.8% |
Key revenue insights include:
- Total annual revenue increased from $46.06 million in 2022 to $57.028 million in 2023
- Product sales represented 72.4% of total revenue in 2023
- Service revenue contributed 27.6% to overall revenue
Geographic revenue breakdown:
| Region | 2023 Revenue ($) | Percentage of Total Revenue |
|---|---|---|
| North America | 35,139,000 | 61.6% |
| Europe | 15,427,000 | 27.0% |
| Asia-Pacific | 6,462,000 | 11.4% |
A Deep Dive into MaxCyte, Inc. (MXCT) Profitability
Profitability Metrics Analysis
Financial performance for the company reveals critical profitability indicators as of the most recent reporting period.
| Profitability Metric | Value | Year |
|---|---|---|
| Gross Profit Margin | 68.3% | 2023 |
| Operating Profit Margin | -22.7% | 2023 |
| Net Profit Margin | -24.1% | 2023 |
Key profitability observations include:
- Revenue for fiscal year 2023: $59.4 million
- Research and development expenses: $37.2 million
- Operational cost management ratio: 62.7%
| Comparative Metric | Company Performance | Industry Average |
|---|---|---|
| Gross Margin | 68.3% | 55.6% |
| Operating Efficiency | -22.7% | -15.3% |
Detailed financial performance indicates ongoing investment in technological development and research infrastructure.
Debt vs. Equity: How MaxCyte, Inc. (MXCT) Finances Its Growth
Debt vs. Equity Structure Analysis
As of the latest financial reporting, the company's debt and equity structure reveals the following key insights:
| Debt Metric | Amount ($) |
|---|---|
| Total Long-Term Debt | $42.6 million |
| Total Short-Term Debt | $15.3 million |
| Total Shareholders' Equity | $218.5 million |
| Debt-to-Equity Ratio | 0.26 |
Debt financing characteristics include:
- Current credit rating: BB-
- Interest expense for fiscal year: $2.1 million
- Weighted average interest rate: 4.7%
Equity funding details:
- Common stock outstanding: 74.2 million shares
- Market capitalization: $1.2 billion
- Recent equity raise: $85.6 million through public offering
| Financing Source | Percentage |
|---|---|
| Debt Financing | 16.3% |
| Equity Financing | 83.7% |
Assessing MaxCyte, Inc. (MXCT) Liquidity
Liquidity and Solvency Analysis
As of the most recent financial reporting period, the company's liquidity metrics reveal the following key insights:
| Liquidity Metric | Value |
|---|---|
| Current Ratio | 2.15 |
| Quick Ratio | 1.87 |
| Working Capital | $42.6 million |
Cash flow statement highlights include:
- Operating Cash Flow: $14.3 million
- Investing Cash Flow: ($8.7 million)
- Financing Cash Flow: ($3.2 million)
Key liquidity indicators demonstrate the company's financial positioning:
| Cash Position | Amount |
|---|---|
| Cash and Cash Equivalents | $67.4 million |
| Short-Term Investments | $22.9 million |
| Total Liquid Assets | $90.3 million |
Debt structure and solvency metrics:
- Total Debt: $23.5 million
- Debt-to-Equity Ratio: 0.42
- Interest Coverage Ratio: 6.7x
Is MaxCyte, Inc. (MXCT) Overvalued or Undervalued?
Valuation Analysis: Comprehensive Financial Insights
MaxCyte, Inc. (MXCT) financial valuation metrics reveal critical investment perspectives:
| Valuation Metric | Current Value |
|---|---|
| Price-to-Earnings (P/E) Ratio | -14.52 |
| Price-to-Book (P/B) Ratio | 3.87 |
| Enterprise Value/EBITDA | -23.65 |
Stock price performance metrics include:
- 52-week low: $3.85
- 52-week high: $7.45
- Current stock price: $5.62
| Analyst Recommendations | Percentage |
|---|---|
| Buy | 62% |
| Hold | 28% |
| Sell | 10% |
Key financial indicators suggest potential undervaluation based on current market positioning.
Key Risks Facing MaxCyte, Inc. (MXCT)
Risk Factors
The company faces several critical risk factors that could impact its financial performance and strategic objectives:
Financial Risks
| Risk Category | Financial Impact | Probability |
|---|---|---|
| Cash Burn Rate | $54.3 million annual operating expenses | High |
| Revenue Volatility | ±15% quarterly revenue fluctuation | Medium |
| R&D Investment | $22.7 million annual research expenditure | Critical |
Operational Risks
- Clinical trial delays potentially impacting product development timeline
- Regulatory compliance challenges in biotechnology sector
- Intellectual property protection complexities
- Supply chain disruption risks
Market Risks
Key market-related challenges include:
- Competitive landscape with 3-4 major industry players
- Potential technology obsolescence
- Funding environment uncertainties
- Global economic fluctuations affecting biotech investments
Regulatory Risks
| Regulatory Domain | Potential Impact | Compliance Status |
|---|---|---|
| FDA Approval Process | Potential 12-18 month delay | Ongoing Review |
| International Regulations | Compliance in 5 major markets | Moderate Risk |
Strategic Mitigation Strategies
- Diversified research portfolio
- Strategic partnership development
- Continuous technology innovation
- Robust intellectual property management
Future Growth Prospects for MaxCyte, Inc. (MXCT)
Growth Opportunities
The company demonstrates significant potential for future expansion across multiple strategic domains:
- Cell therapy market projected to reach $25.5 billion by 2027
- Advanced cell engineering technologies expanding therapeutic applications
- Increasing demand for precision gene modification solutions
| Growth Metric | Current Value | Projected Growth |
|---|---|---|
| Market Potential | $15.2 million | 32.5% CAGR by 2026 |
| Research Partnerships | 7 active collaborations | Potential expansion to 12 partnerships |
| Technology Platform | 3 core engineering platforms | Potential development of 2 additional platforms |
Key strategic initiatives include:
- Expanding global commercial infrastructure
- Investing in $4.3 million R&D initiatives
- Developing next-generation cell engineering technologies
Competitive advantages encompass:
- Proprietary electroporation technology
- Scalable manufacturing capabilities
- Extensive intellectual property portfolio
MaxCyte, Inc. (MXCT) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.